Vera Therapeutics, Inc. (VERA)
| Market Cap | 2.32B +71.1% |
| Revenue (ttm) | n/a |
| Net Income | -368.95M |
| EPS | -5.57 |
| Shares Out | 71.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,515,652 |
| Open | 33.38 |
| Previous Close | 33.38 |
| Day's Range | 31.40 - 34.06 |
| 52-Week Range | 19.07 - 56.05 |
| Beta | 0.95 |
| Analysts | Strong Buy |
| Price Target | 78.00 (+141.56%) |
| Earnings Date | May 7, 2026 |
About VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for VERA stock is "Strong Buy." The 12-month stock price target is $78.0, which is an increase of 141.56% from the latest price.
News
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on June 2, 2026, the Compensation Committee of the Board of Directors (Compensation Com...
Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis
Vera Therapeutics (VERA) announced it has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support full approval for atacicept in…
Raymond James sees unique buying opportunity in Vera after FDA alignment
Raymond James notes Strong Buy-rated Vera Therapeutics (VERA) announced it has alignment with FDA to carry out an earlier Phase 3 eGFR analysis to potentially support full approval for atacicept…
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgAN
Vera Therapeutics Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were raised, and quorum was confirmed. Final voting results will be filed on Form 8-K.
Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI
Evercore ISI lowered the firm’s price target on Vera Therapeutics (VERA) to $91 from $95 and keeps an Outperform rating on the shares.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on May 4, 2026, the Compensation Committee of the Board of Directors (Compensation Commi...
Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37)
“The team at Vera Therapeutics (VERA) is focused on execution as we advance atacicept toward potential FDA accelerated approval in IgAN,” said Marshall Fordyce, Founder and CEO of Vera Therapeutics.
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
U.S. Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Pr...
Vera Therapeutics Earnings release: Q1 2026
Vera Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Vera Therapeutics Quarterly report: Q1 2026
Vera Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Vera Therapeutics to Participate in the Bank of America Securities 2026 Health Care Conference
BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with...
Vera Therapeutics Proxy statement: Proxy filing
Vera Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Vera Therapeutics Proxy statement: Proxy filing
Vera Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients wi...
Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research analyst Andy Chen upgraded Vera Therapeutics (VERA) to Outperform from Peer Perform with an $88 price target. Vertex’s (VRTX) reported interim data from its Phase 3 trial of…
Vertex poses ‘no threat’ to Vera Therapeutics’ atacicept, says BofA
After Vertex (VRTX) reported interim data from its Phase 3 trial of povetacicept in IgA nephropathy patients, BofA said the topline data, which was in-line with the firm’s base case…
Vera Therapeutics appoints Hite to Board of Directors
Vera Therapeutics (VERA) announced the appointment of Christopher Hite to Vera Therapeutics’ Board of Directors.
Vera Therapeutics Appoints Christopher Hite to Board of Directors
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients wi...
Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Atacicept is on track for FDA approval in July, with strong clinical data and a broad label anticipated. Commercial launch preparations are advanced, targeting a large, young, commercially insured U.S. population, and leveraging a patient-friendly auto-injector. Ongoing studies and a robust IP portfolio support future growth.
Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a Buy rating on the shares. The firm updated the company’s model after…
Vera Therapeutics reports FY25 EPS ($4.66), consensus ($4.44)
“In 2025, Vera Therapeutics (VERA) delivered on several key milestones as we advanced atacicept toward potential FDA approval and commercialization,” said Marshall Fordyce, M.D., Founder and CEO of Ve...
Vera Therapeutics sees cash runway through atacicept commercial launch
Vera Therapeutics (VERA) reported $714.6 million in cash, cash equivalents, and marketable securities as of December 31, 2025, which combined with availability under its debt facility, Vera Therapeuti...
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Positive Phase 3 data from ORIGIN 3 study of atacicept in IgA nephropathy (IgAN) presented at American Society of Nephrology (ASN) Kidney Week and published in the New England Journal of Medicine U.S....
Vera Therapeutics Annual report: Q4 2025
Vera Therapeutics has published its Q4 2025 annual report on February 26, 2026.